Tandem Diabetes Care (TNDM) EPS (Weighted Average and Diluted) (2018 - 2026)
Tandem Diabetes Care (TNDM) reported EPS (Weighted Average and Diluted) of -$0.3 for Q1 2026, up 84.77% on a YoY basis from -$0.16 in Q1 2025, and down 2900.0% quarter-over-quarter from -$0.01 in Q4 2025.
Tandem Diabetes Care (TNDM) EPS (Weighted Average and Diluted) (2018 - 2026) Analysis & Trends
Tandem Diabetes Care has reported EPS (Weighted Average and Diluted) for 9 years, with the latest figure at -$0.3 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 84.77% year-over-year to -$0.3; the trailing twelve-month figure through Mar 2026 stood at -$1.4 (up 49.64% YoY), and the FY2025 full-year result was -$3.04, down 106.8% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.3, down from -$0.01 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $0.01 in Q4 2024, with the low at -$1.97 in Q1 2025.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.57 across 5 years, with a median of -$0.46 in 2023.
- Annual changes were most pronounced in 2022 — EPS (Weighted Average and Diluted) plunged 944.44% — and 2024, when it surged 102.17%.
- Tandem Diabetes Care's EPS (Weighted Average and Diluted) stood at -$0.25 in 2022, then plunged by 84.0% to -$0.46 in 2023, then surged by 102.17% to $0.01 in 2024, then slumped by 200.0% to -$0.01 in 2025, then sank by 2900.0% to -$0.3 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.3 (Q1 2026), -$0.01 (Q4 2025), and -$0.31 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 0.61 |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 1.93 |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 0.89 |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 0.90 |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 0.66 |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 0.51 |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 0.85 |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 2.24 |
| 10 | Tandem Diabetes Care | 1.04 Bn | 474.17 Mn | 136.79 Mn | -0.30 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.30 |
| Dec 31, 2025 | -0.01 |
| Sep 30, 2025 | -0.31 |
| Jun 30, 2025 | -0.78 |
| Mar 31, 2025 | -1.97 |
| Dec 31, 2024 | 0.01 |
| Sep 30, 2024 | -0.35 |
| Jun 30, 2024 | -0.47 |
| Mar 31, 2024 | -0.65 |
| Dec 31, 2023 | -0.46 |
| Sep 30, 2023 | -0.51 |
| Jun 30, 2023 | -0.55 |
| Mar 31, 2023 | -1.92 |
| Dec 31, 2022 | -0.25 |
| Sep 30, 2022 | -0.76 |
| Jun 30, 2022 | -0.24 |
| Mar 31, 2022 | -0.23 |
| Dec 31, 2021 | 0.16 |
| Sep 30, 2021 | 0.09 |
| Jun 30, 2021 | 0.06 |